Nkarta Stock News

Charles Schwab Investment Management Inc. reduced its holdings in Nkarta, Inc. (NASDAQ:NKTX) by 9.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,615 shares of the companys stock after selling 11,482 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately []

Nkarta Inc. (NASDAQ:NKTX)s traded shares stood at 0.44 million during the last session. At the close of trading, the stocks price was $17.37, to imply a decrease of -2.47% or -$0.44 in intraday trading. The NKTX shares 52-week high remains $79.16, putting it -355.73% down since that peak but still an impressive 10.13% since price At Current Prices, Nkarta Inc. (NASDAQ: NKTX) Worth A Patient Look? Read More »

Northern Trust Corp cut its stake in shares of Nkarta, Inc. (NASDAQ:NKTX) by 28.0% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 159,529 shares of the companys stock after selling 62,111 shares during the period. Northern Trust Corp owned approximately 0.49% of Nkarta worth $5,056,000 at []

Research analysts at Sumitomo Mitsui Financial Group began coverage on shares of Nkarta (NASDAQ:NKTX) in a research note issued on Thursday, Briefing.com reports. The firm set an outperform rating and a $50.00 price target on the stock. Sumitomo Mitsui Financial Groups price target indicates a potential upside of 185.55% from the stocks previous close. Several []

The mean of analysts' price targets for Nkarta (NKTX) points to a 270.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts

The mean of analysts' price targets for Nkarta (NKTX) points to a 270.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today

Nkarta Inc (NASDAQ: NKTX) has updated guidance on initial data readout of Phase 1 trial of NKX101 in relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes. Data fro

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today

Nkarta Therapeutics Inc (NASDAQ: NKTX) will be moving into an 88,000-square-foot facility that will not only serve as its newest headquarters but will support the research, development, and future

SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today

SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today

Unfortunately, this isn't an endorsement by a big drug developer.